Furthermore, this analog inhibits endothelial cell proliferation with IC50 values in the pM range that are 2.7- to 214-fold lower than those of other antiangiogenic proteins (endostatin and angiostatin) and peptides (anginex and cilengitide) tested in cancer clinical trials [11]. Here, COL18A1 is linked to cancer.